Navigation Links
Relieving chronic pain

Each year, more than 35,000 patients in the United States are implanted with spinal cord stimulators to treat chronic pain. Unfortunately, up to half of such patients receive only very limited pain relief. To help more patients, scientists are developing a new device to deliver therapeutic stimulation in a more targeted way, reaching nerve fibers deep within the spinal cord.

Standard devices, first introduced in 1967, work by delivering a low electrical current to the spinal cord that interferes with the body's pain signals. Such devices, however, are only able to deliver therapeutic current to a thin layer of nerve fibers along the outside of the spinal cord. That's because the electrodes delivering the current are placed within the cerebrospinal fluid, which is itself conductive and so dissipates some of the current.

The new device, called the Human Spinal Cord Modulation System (HSCMS), is designed to be in direct contact with the spinal cord, held in place by a small loop of wire. Because the spinal cord moves during normal patient activity, that loop has to exert enough pressure for the HSCMS to stay in contact with the spinal cord but not so much that the pressure restricts blood flow or causes direct injury.

To test the pressure exerted by the HSCMS's design, researchers attached the device to a silicone model of the spinal cord previously developed to have the same biomechanical characteristics as living tissue. They then slowly compressed the loop, measuring the pressure exerted on the silicone model. The results, which were accepted for publication in the American Institute of Physics (AIP) Journal of Applied Physics, show the device's loop design exerts pressure at a similar level as is normally found on the spinal cords of healthy people, and so passes an important safety test for further development of the device.

Contact: Catherine Meyers
American Institute of Physics

Page: 1

Related biology news :

1. Relieving plant stress could eventually help humans relax
2. Are survivors of childhood leukemia and lymphoma at greater risk of chronic fatigue as adults?
3. NIH awards nearly $2 million to 3 NYC institutions for chronic fatigue syndrome research
4. Preventing chronic pain with stress management
5. Virology researcher awarded nearly $2 million to study chronic hepatitis E
6. Loneliness, like chronic stress, taxes the immune system
7. Chronic disease research awarded funding
8. Social synchronicity
9. Chronic kidney disease increases risk of death at all ages
10. Viruses not to blame for chronic fatigue syndrome after all
11. B cell survival holds key to chronic graft vs. host disease
Post Your Comments:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology: